Is it time for mental health services to invest in neurostimulation? An economic evaluation of transcranial magnetic stimulation therapies for the treatment of moderate to severe treatment-resistant depression in the UK

Key Points

• Transcranial magnetic stimulation is identified as a viable cost-effective option for managing treatment-resistant depression.
• Key evidence from the economic evaluation supports that TMS can reduce overall healthcare costs significantly compared to traditional therapies.
• The assessment analyzed treatment outcomes and costs, focusing on patients with moderate to severe depression after inadequate response to prior treatments.
• This finding highlights the need for investment in neurostimulation therapies, as it may lead to improved patient outcomes and reduced healthcare burden.

Abstract